Recent Updates — ZVSA

July 16, 2026View Source ↗

ZyVersa Therapeutics, Inc. transitioned from trading on the OTCQB Venture Market to the OTC Pink Limited Market effective July 16, 2026. The company is a biotechnology company focused on developing and commercializing commercial-grade skin barrier protection products.

July 10, 2026View Source ↗

ZyVersa Therapeutics, Inc. announced the immediate resignation of independent director Min Chul Park, Ph.D., and is exploring cost-cutting measures to preserve cash, including potential product candidate divestitures, headcount reductions, and the possibility of suspending its SEC reporting obligations. CEO Stephen Glover and CFO Peter Wolfe have voluntarily accepted reduced compensation to support the company. ZyVersa Therapeutics, Inc. is a biotechnology company focused on developing therapeutic products.